Merck 's Odanacatib-a better osteoporosis drug?
Merck could really use a better name for its new drug Odanacatib...if it wants the medication to become a household name.
Odanacatib has been tested in post-menopausal women with osteoporosis since 2007 and has now successfully completed its phase 3 study. The company will request regulatory approval from the U.S., EU and Japan in 2013.
Merck expects the drug to earn $800 million in 2016 if it competes successfully with Amgen's drug Proliprea.
Wow! People spend a lot on medication when prevention with vitamins and minerals would be far more effective for the vast majority.
Click here to post comments.
Join in and write your own page! It's easy to do. How?
Simply click here to return to Vitamins Forum.